SML2805

Narciclasine

≥98% (HPLC)

• Sinónimos: Narciclasine, (2S-(2-alpha,3-beta,4-beta,4a-beta))-3,4,4a,5-tetrahydro-2,3,4,7-tetrahydroxy-(1,3)Dioxolo(4,5-j)phenanthridin-6(2H)-one, 3,4,4a,5-Tetrahydro-2,3,4,7-tetrahydroxy-(1,3)dioxolo(4,5-j)phenanthridin-6(2H)-one, BRN 1087400, Lycoricidin-A, Lycoricidinol, NSC 266535
• Fórmula empírica (notación de Hill): C₁₄H₁₃NO₇
• Número de CAS: 29477-83-6
• Peso molecular: 307.26
• MDL number: MFCD01729949
• UNSPSC Code: 12352200
• NACRES: NA.77

Propiedades

• Quality Level: 100
• assay: ≥98% (HPLC)
• form: powder
• optical activity: [α]/D 167 to 187° in DMSO
• color: white to beige
• solubility: DMSO: 2 mg/mL, clear
• storage temp.: −20°C
• SMILES string: O[C@H]1C=C2[C@@H](NC(=O)c3c(O)c4OCOc4cc23)[C@H](O)[C@@H]1O
• InChI: 1S/C14H13NO7/c16-6-1-5-4-2-7-13(22-3-21-7)11(18)8(4)14(20)15-9(5)12(19)10(6)17/h1-2,6,9-10,12,16-19H,3H2,(H,15,20)/t6-,9+,10+,12-/m0/s1
• InChI key: LZAZURSABQIKGB-AEKGRLRDSA-N

Descripción

Biochem/physiol Actions

Narciclasine is a Rho/Rho kinase/LIM kinase/cofilin signaling pathway activator. Also narciclasine is an actin stress fiber formation inducer; a plant growth modulator.

Recent report in Blood Identified cinobufagin, anisomycin and narciclasine as novel expression-mimickers (Ems) that exert in vitro as well as in vivo anti-AML efficacy against AML expressing mtRUNX1. Recent report identifies cinobufagin, anisomycin and narciclasine as novel expression-mimickers (Ems) that exert in vitro as well as in vivo anti-AML efficacy against AML expressing mtRUNX1.

Información de seguridad

• pictograms: GHS06
• signalword: Danger
• hcodes: H301
• pcodes: P264 - P270 - P301 + P310 - P405 - P501
• Hazard Classifications: Acute Tox. 3 Oral
• Storage Class: 6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
• wgk_germany: WGK 3
• flash_point_f: Not applicable
• flash_point_c: Not applicable